Volume 8, Issue 9.
In this issue:
The effects of CFTR modifiers on improving lung function in people with cystic fibrosis are well known. But what about their effects on the GI tract that directly affect nutrition?
In this issue, Dr. Michael Wilschanski — Director of Hadassah Hospital’s Pediatric Gastroenterology Unit at Hebrew University in Jerusalem — explains how new findings about CFTR modification can impact clinical practice.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Podcast (ecystic): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS